Advances in translational therapy for locally advanced gastric cancer

Table 1 Research on postoperative chemotherapy and radiochemotherapy for locally advanced gastric cancer

Title of research study	Year	Country/district	Study design	Study assignment	Surgical procedure	Complete percentage	3-yr progression-free survival	Overall survival
ARTIST	2012	South Korea	Phase 3 randomized controlled study	Surgery + XP (228 cases); Surgery + XP + radiotherapy (230 cases)	D2	82%; 75%	74.2%; 78.2%	73%; 75%
INT-0116	2012	North America	Phase 3 randomized controlled study	Surgery (277 cases); R0 + radiotherapy/fluorouracil (282 cases)	D2	96%; 65%	-	-
CLASSIC	2014	Eastern Asia	Phase 3 randomized controlled study	Surgery (515 cases); Surgery + XELOX (520 cases)	D2	83%; 67%	59%; 74%	69%; 78%
RESOLVE	2021	China	Phase 3 randomized controlled study	Surgery + XELOX (364 cases); Surgery + SOX (364 cases); SOX + surgery + SOX\S-1 (365 cases)	D2	70%; 68%; 58%	51.1%; 56.5%; 59.4%	-
ARTIST Ⅱ	2021	South Korea	Phase 3 randomized controlled study	Surgery + S-1; Surgery + SOX (181 cases); Surgery + SOX + radiotherapy (183 cases)	D2	71%; 85%; 83%	64.8%; 74.3%; 72.8%	-
JACCROGC-07	2022	Japan	Phase 3 randomized controlled study	Surgery + S-1; Surgery + S-1 + docetaxel (456 cases)	D2	80%; 40%	57.4%; 67.7%	71.2%; 77.7%